Central Banks Shift to "Higher for Longer" Rates Amid Inflation: As a clinical-stage biotechnology company, Cabaletta Bio relies heavily on funding for research and development. Higher interest rates increase the cost of borrowing and can make it more challenging to secure capital for ongoing clinical trials and future growth, directly impacting its financial viability and valuation.

Iran War Escalation Drives US Inflation to 3.3%: Increased geopolitical instability and persistent inflation contribute to a "risk-off" sentiment among investors. This environment typically leads to a reallocation of capital away from speculative growth stocks, such as pre-revenue biotechs like CABA, towards more stable and less volatile assets. High inflation can also increase operational costs for R&D.

Q1 2026 Earnings Season Kicks Off with Major US Banks: While not directly in the banking sector, the broader market's reaction to the Q1 2026 earnings season, particularly insights into the economic outlook and consumer/business confidence from major financial institutions, can influence overall investor sentiment and risk appetite. A cautious or negative outlook could dampen enthusiasm for the broader market, including the biotech sector, affecting CABA's stock performance.